STAAR Surgical vs Neogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

STAAR Surgical Company (STAA)

Q3 202617 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

August 202617 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

Latest17 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

Neogen Corporation (NEOG)

Q3 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest24 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.